209225-01-4

Basic information

• Product Name: 1H-Indene-2-carboxylicacid,2,3-dihydro-5-nitro-(9CI)
• Synonyms: 1H-Indene-2-carboxylicacid,2,3-dihydro-5-nitro-(9CI);5-nitro-2,3-dihydro-1H-indene-2-carboxylic acid
• CAS NO: 209225-01-4
• Molecular Formula: C10H9NO4
• Molecular Weight: 207.18276
• Product Categories: AMINOACID
• Mol File: 209225-01-4.mol

Chemical Properties

• Melting Point: 122.5 °C(Solv: water (7732-18-5))
• Boiling Point: 410.8±45.0 °C(Predicted)
• Appearance: /
• Density: 1.452±0.06 g/cm3(Predicted)
• PKA: 4.18±0.20(Predicted)
• CAS DataBase Reference: 1H-Indene-2-carboxylicacid,2,3-dihydro-5-nitro-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Indene-2-carboxylicacid,2,3-dihydro-5-nitro-(9CI)(209225-01-4)
• EPA Substance Registry System: 1H-Indene-2-carboxylicacid,2,3-dihydro-5-nitro-(9CI)(209225-01-4)

Safety Data

• Hazardous Substances Data: 209225-01-4(Hazardous Substances Data)

Upstream product

• 25177-85-9 2-indancarboxylic acid 
• 179266-54-7 ethyl 5-nitroindane-2-carboxylate 
• 26453-01-0 1H-indene-2-carbonitrile, 2,3-dihydro- 
• 91-13-4 α,α'-dibromo-o-xylene 
• 6425-66-7 1,2-bis-bromomethyl-4-nitro-benzene 
• 2437-08-3 indane-2,2-dicarboxylic acid 
• 871899-86-4 5-nitro-indan-2,2-dicarboxylic acid 
• 100-66-3 methoxybenzene 

Relevant articles and documents

Tricyclic [1,2,4]triazine 1,4-dioxides as hypoxia selective cytotoxins

A series of novel tricyclic triazine-di-N-oxides (TTOs) related to tirapazamine have been designed and prepared. A wide range of structural arrangements with cycloalkyl, oxygen-, and nitrogen-containing saturated rings fused to the triazine core, coupled with various side chains linked to either hemisphere, resulted in TTO analogues that displayed hypoxia-selective cytotoxicity in vitro. Optimal rates of hypoxic metabolism and tissue diffusion coefficients were achieved with fused cycloalkyl rings in combination with both the 3-aminoalkyl or 3-alkyl substituents linked to weakly basic soluble amines. The selection was further refined using pharmacokinetic/pharmacodynamic model predictions of the in vivo hypoxic potency (AUCreq) and selectivity (HCD) with 12 TTO analogues predicted to be active in vivo, subject to the achievement of adequate plasma pharmacokinetics.

TRICYCLIC 1,2,4-TRIAZINE OXIDES AND COMPOSITIONS THEREFROM FOR THERAPEUTIC USE IN CANCER TREATMENTS

The invention relates to novel tricyclic 1,2,4-triazine-1-oxides and novel tricyclic 1,2,4-triazine-1,4-dioxides of formula: (I); and to related analogues, to their preparation, and to their use as hypoxia-selective drugs and radiosensitizers for cancer therapy, both alone or in combination with radiation and/or other anticancer drugs.

Indane or dihydroindole derivatives

The present invention relates to substituted indane or dihydroindole compounds of Formula (I) wherein A is an indole. These compounds have high affinity for D4receptors.

Indane or dihydroindole derivatives

The present invention relates to substituted indane or dihydroindole compounds of Formula (I) wherein A is an indole. These compounds have high affinity for D4receptors.

Pyrazole derivatives

The present invention relates to a compound represented by the general formula [I]: wherein A and B rings are ortho-condensed to each other, A ring represents an aromatic carbocyclic or heterocyclic ring and B ring represents an aliphatic four- to seven-m